Taken together, these results indicate that 4T1.2/HER2 cells can induce antitumor immunity-mediated tumor regression and that CT26/HER2 cells are unable to induce antitumor immunity but remain sensitive to the antitumor immunity induced by 4T1.2/HER2 cells. Here, ERBB2 is linked to neoplasm.